Camber-logo (Camber Logo)
Duloxetine Capsule, Delayed Release
Product Images NDC 31722-170
14 FDA label images from Camber Pharmaceuticals, Inc. · Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 31722-170). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Camber Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Duloxetinedrcapsules20mg60scount (Duloxetinedrcapsules20mg60scount)
Label for Duloxetine Delayed-release Capsules USP 20 mg by Camber Pharmaceuticals, Inc. The label shows the NDC 31722-168-60 and indicates a package count of 60 capsules. It includes storage instructions, usage advice, manufacturer details, and a barcode.*
Duloxetinedrcapsules30mg30scount (Duloxetinedrcapsules30mg30scount)
Label for Duloxetine Delayed-release Capsules USP, 30 mg strength, manufactured for Camber Pharmaceuticals, Inc. The label includes product identification, dosage form, package count of 30 capsules, and storage instructions. It also features a barcode, contact information, and a caution for pharmacists to dispense the medication guide separately.*
Duloxetinedrcapsules60mg30scount (Duloxetinedrcapsules60mg30scount)
The label for Duloxetine delayed-release capsules, USP 60 mg by Camber Pharmaceuticals, Inc. The label includes dosage instructions, storage conditions, and a barcode. It indicates a package size of 30 capsules and states 'Rx Only'. The label also provides contact information and manufacturing details, including Hetero Labs Limited in Hyderabad, India.*
Duloxetinestructure (Duloxetinestructure)
Chemical structure diagram of duloxetine hydrochloride showing its molecular arrangement, including a thiophene ring, a naphthalene group, and hydrochloride salt component.*
Figure1 (Figure1)
A line graph showing the proportion of patients with relapse over time in days from randomization. The graph compares patients treated with Duloxetine versus placebo, with the x-axis representing time in days (0 to 250) and the y-axis representing the proportion of patients with relapse (0.0 to 1.0).*
Figure10 (Figure10)
A line graph comparing percentage improvement in pain from baseline (BOCF) on the x-axis with cumulative percentage of patients improved on the y-axis for Duloxetine 60/120 mg once daily versus placebo. The graph shows two lines illustrating patient improvement distributions for each treatment group.*
Figure2 (Figure2)
A Kaplan-Meier curve graph showing the proportion of patients with relapse over time (days) from randomization, comparing Duloxetine treatment to placebo. The x-axis represents time in days up to 300, and the y-axis shows the proportion of patients relapsed ranging from 0 to 1. The Duloxetine group has a consistently lower proportion of relapse than the placebo group throughout the study period.*
Figure3 (Figure3)
Line graph showing the percentage of patients improved versus percent improvement in pain from baseline for Duloxetine at 20 mg QD, 60 mg QD, 60 mg BID, and placebo. The graph compares patient response rates across increasing pain improvement thresholds.*
Figure4 (Figure4)
A line graph showing the percentage of patients improved plotted against percent improvement in pain from baseline. It compares three groups: Duloxetine 60 mg twice daily (BID), Duloxetine 60 mg once daily (QD), and placebo, with Duloxetine groups showing higher improvement percentages at various pain improvement levels.*
Figure5 (Figure5)
A line graph displaying the percentage of patients improved plotted against the percent improvement in pain from baseline. The graph compares duloxetine 60 mg taken twice daily, duloxetine 60 mg taken once daily, and placebo, showing their effectiveness in pain improvement over a range of percentages.*
Figure6 (Figure6)
Line chart showing the percentage of patients improved versus percent improvement in pain from baseline for Duloxetine at 120 mg, 60 mg, 20 mg once daily doses compared to placebo. The chart displays data indicating improvements across a range of pain relief percentages.*
Figure8 (Figure8)
A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF) for placebo and duloxetine 60/120 mg once daily. The x-axis shows percent improvement in pain from 0 to 100+, and the y-axis shows the percentage of patients improved from 0 to 100%. Two lines represent placebo and duloxetine treatment groups.*
Figure9 (Figure9)
A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline for Duloxetine 60 mg once daily and placebo groups. The x-axis represents percent improvement in pain from baseline (BOCF), and the y-axis shows the percentage of patients improved. Duloxetine shows higher improvement rates across the range compared to placebo.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
